InvestorsHub Logo
Followers 91
Posts 11334
Boards Moderated 0
Alias Born 06/06/2014

Re: stockaesthetics post# 76824

Friday, 09/30/2016 10:15:59 AM

Friday, September 30, 2016 10:15:59 AM

Post# of 461963
Opicinumab just finished two Phase 2's and the results were disappointing but had hints of some effect.

Neuroinflammation is theorized to be part of many CNS pathologies and MS is no exception. I think what is happening is that 2-73 is going to be thrown at everything to see if something sticks. Soooo many variables though: dosing, disease stage, agent combos, etc. Shots in the dark.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News